Association of CSF GAP-43 and APOE ε4 with Cognition in Mild Cognitive Impairment and Alzheimer’s Disease
Authors:
- Yueli ZhuYZYueli Zhu
- Xiaoming GuoXGXiaoming Guo
- Feng ZhuFZFeng Zhu
- Qin ZhangQZQin Zhang
- Yunmei YangYYYunmei Yang
- For The Alzheimer’s Disease Neuroimaging InitiativeFIFor The Alzheimer’s Disease Neuroimaging Initiative
Open Access
Abstract
The growth-associated protein 43 (GAP-43) is a presynaptic phosphoprotein in cerebrospinal fluid (CSF). The ε4 allele of apolipoprotein E (APOE) is an important genetic risk factor for Alzheimer’s disease (AD). We aimed to evaluate the association of CSF GAP-43 with cognition and whether this correlation was related to the APOE ε4 status. We recruited participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, and they were divided into cognitively normal (CN) ε4 negative (CN ε4−), CN ε4 positive (CN ε4+), mild cognitive impairment (MCI) ε4 negative (MCI ε4−), MCI ε4 positive (MCI ε4+), AD ε4 negative (AD ε4−), and AD ε4 positive (AD ε4+) groups. Spearman’s correlation was utilized to evaluate the relationship between CSF GAP-43 and core AD biomarkers at the baseline. We performed receiver-operating characteristic (ROC) curve analyses to investigate the diagnostic accuracy of CSF GAP-43. The correlations between CSF GAP-43 and the Mini-Mental State Examination (MMSE) scores and brain atrophy at baseline were assessed by using multiple linear regression, while the association between CSF GAP-43 and MMSE scores at the follow-up was tested by performing the generalized estimating equation (GEE). The role of CSF GAP-43 in the conversion from MCI to AD was evaluated using the Cox proportional hazard model. We found that the CSF GAP-43 level was significantly increased in MCI ε4+, AD ε4− and AD ε4+ groups compared with CN ε4− or MCI ε4− group. The negative associations between the CSF GAP-43 and MMSE scores at the baseline and follow-up were found in MCI ε4− and MCI ε4+ groups. In addition, baseline CSF GAP-43 was able to predict the clinical progression from MCI to AD. CSF GAP-43 may be a promising biomarker to screen cognition for AD. The effects of CSF GAP-43 on cognition were suspected to be relevant to APOE ε4 status.Keywords
Funding Information
- Key R&D Program of Zhejiang (2022C03161, 81771498)
- National Natural Science Foundation of China (2022C03161, 81771498)
This publication has 31 references indexed in Scilit:
- Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of NeurodegenerationNeuron, 2010
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methodsJournal of Magnetic Resonance Imaging, 2008
- Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairmentNeurology, 2007
- Non‐fibrillar β‐amyloid abates spike‐timing‐dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptorsEuropean Journal of Neuroscience, 2006
- Soluble β-Amyloid1-40Induces NMDA-Dependent Degradation of Postsynaptic Density-95 at Glutamatergic SynapsesJournal of Neuroscience, 2005
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991
- Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severityAnnals of Neurology, 1990
- The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's diseaseNeurology, 1988